Presbia (OTCMKTS:LENSF) and Bioventus (NYSE:BVS) Financial Survey

Presbia (OTCMKTS:LENSF) and Bioventus (NYSE:BVS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, dividends, profitability, earnings, risk, analyst recommendations and institutional ownership.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Presbia and Bioventus, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Presbia	0	0	0	0	0.00
Bioventus	0	1	3	0	2.75

Bioventus has a consensus price target of $13.75, suggesting a potential upside of 96.43%. Given Bioventus’ stronger consensus rating and higher probable upside, analysts plainly believe Bioventus is more favorable than Presbia.

Earnings & Valuation

This table compares Presbia and Bioventus”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Presbia	N/A	N/A	N/A	N/A	N/A
Bioventus	$564.14 million	1.03	-$156.23 million	N/A	N/A

Presbia has higher earnings, but lower revenue than Bioventus.

Institutional and Insider Ownership

62.9% of Bioventus shares are owned by institutional investors. 74.2% of Presbia shares are owned by insiders. Comparatively, 33.0% of Bioventus shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Volatility & Risk

Presbia has a beta of 5.91, meaning that its stock price is 491% more volatile than the S&P 500. Comparatively, Bioventus has a beta of 0.84, meaning that its stock price is 16% less volatile than the S&P 500.

Profitability

This table compares Presbia and Bioventus’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Presbia	N/A	N/A	N/A
Bioventus	-7.11%	15.61%	4.01%

Summary

Bioventus beats Presbia on 7 of the 10 factors compared between the two stocks.

About Presbia

Presbia PLC, an ophthalmic device company, develops and markets optical lens implants for treating presbyopia. The company provides the refractive lens for patient surgeries, as well as accessories for procedures. It primarily operates in the United States, South Korea, Australia, Italy, the Netherlands, Ireland, Canada, and Germany. The company was founded in 2014 and is headquartered in Dublin, Ireland.

About Bioventus

Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise bone graft substitutes that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries; and ultrasonic products used for precise bone cutting and sculpting, soft tissue management, and tissue debridement, in various surgeries, including minimally invasive applications. The company's product include, Osteoamp, an allograft-derived bone graft for bone grafting procedures; Exponent matrix for posterolateral spine procedures; Purebone for bone grafting procedures; Signafuse bone graft; Interfuse bone graft; Osteomatrix+ synthetic bone graft; Extractor for autologous cell and bone marrow extraction; reficio bone matrix; nexus ultrasonic surgical system; bonescalpel surgical solution; SonaStar for surgical procedures; and SonicOne ultrasonic cleansing and debridement system. The company's restorative therapies include a bone stimulation system and devices to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. Its products include exogen, a bone healing system; L300 GO, a foot drop system; H200 rehabilitation system; Vector, a body weight support system; and Bioness integrated therapy system. It developing Talisman pulse generator and receiver for peripheral nerve stimulation. The company was founded in 2011 and is headquartered in Durham, North Carolina.